Monoclonal antibody STRO-4
View Patent ↗The present invention relates to a monoclonal antibody designated STRO-4 which specifically binds human and ovine HSP-90beta and its use for enriching multipotential cells such as mesenchymal precursor cells (MPCs).
1. A method for identifying the presence of adult multipotential cells in a sample of cells, the method comprising contacting cells in the sample with an HSP-90beta binding agent or an HSP-90beta binding fragment thereof, wherein the HSP90-beta binding agent is the STRO-4 monoclonal antibody produced by the hybridoma cell line deposited under ATCC Accession Number PTA-9362, or a binding fragment thereof, or an antibody or antigen-binding fragment which binds to the same epitope as the STRO-4 monoclonal antibody; and detecting cells to which such STRO-4 antibody or binding fragment thereof or such antibody or antigen-binding fragment which binds to the same epitope as the STRO-4 antibody binds, so as to identify the presence of cells in the sample that express the HSP-90beta marker and thereby, the presence of the adult multipotential cells in the sample.
2. A method according to claim 1 , wherein the identification of the presence of cells that express the HSP-90beta marker in the sample comprises:
obtaining the sample of cells from a tissue source;
contacting the sample of cells with the HSP-90beta binding agent; and
detecting the presence of the HSP-90beta binding agent bound to cells in the sample, wherein the presence of adult multipotential cells is indicated by cells having bound to the HSP-90beta binding agent.
3. A method according to claim 2 , wherein the tissue source is placenta, adipose tissue, teeth, dental pulp, skin, liver, kidney, heart, retina, brain, hair follicles, intestine, lung, spleen, lymph node, thymus, ovary, pancreas, bone, ligament, bone marrow, tendon or skeletal muscle.
4. A method according to claim 1 , wherein the HSP-90beta binding agent or HSP-90beta binding fragment thereof is selected from the group consisting of:
(i) the STRO-4 monoclonal antibody produced by the hybridoma cell line deposited under ATCC Accession Number PTA-9362;
(ii) a chimeric antibody comprising heavy and light chain variable regions from the STRO-4 monoclonal antibody and human heavy and light chain constant regions; and
(iii) a humanized antibody comprising at least one complementarity determining region (CDR) from STRO-4 and human framework and constant region sequences.